Default company panoramic image
Logo

Traverse Biosciences, Inc.

TRB-N0224 is envisioned as the first FDA-approved, once-daily edible prescription medication for the prevention and control of canine periodontal disease.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Stony Brook, NY, USA
  • Currency USD
  • Founded June 2013
  • Employees 1
  • Incorporation Type C-corp
  • Website traversebiosciences.com

Only investors on Gust who have been granted access can view this content.

Interested in this startup? Sign In or Sign Up to request more information.